Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Rocket Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company. The Company focuses on developing gene therapy treatment options for undertreated diseases, genetic disease that leads to bone marrow failure and potentially cancer, and pediatric disease. Rocket Pharmaceuticals serves patients in the United States.
Website: rocketpharma.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.04 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 96.7% (LTM)

Entry Point: Share price is 34.8% higher than minimum and 90.2% lower than maximum for the last 3 years

Insiders: For the last 3 months insiders sold company shares on $0.1 mln (-0.021% of cap.)

Key Financials (Download financials)

Ticker: RCKT
Share price, USD:  (-2.2%)3.14
year average price 11.30  


year start price 25.33 2024-07-27

max close price 25.33 2024-07-27

min close price 2.33 2025-05-27

current price 3.14 2025-07-26
Common stocks: 68 148 925

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 214
Net Debt ($m): -237
EV (Enterprise Value): -23
Price to Book: 0.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-07-25globenewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. Lawsuit – RCKT

2025-07-25globenewswire.com

FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action – Hagens Berman

2025-07-25globenewswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

2025-07-25prnewswire.com

Levi & Korsinsky Reminds Rocket Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - RCKT

2025-07-24prnewswire.com

RCKT LAWSUIT ALERT: The Gross Law Firm Notifies Rocket Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

2025-07-23prnewswire.com

RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

2025-07-23prnewswire.com

RCKT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In RCKT To Contact Him Directly To Discuss Their Options

2025-07-22globenewswire.com

Investors in Rocket Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights – RCKT

2025-07-22prnewswire.com

Levi & Korsinsky Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - RCKT

2025-07-21prnewswire.com

Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) - August 11, 2025 Deadline to Join - Contact The Gross Law Firm
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-07 2024-08-06 2024-05-07 2024-02-27 2023-11-07 2023-08-09 2023-05-05 2023-02-28 2022-11-04
acceptedDate 2024-11-07 16:45:24 2024-08-06 16:15:31 2024-05-07 16:05:55 2024-02-27 16:05:52 2023-11-07 16:40:36 2023-08-09 17:21:03 2023-05-05 16:41:24 2023-02-28 17:31:33 2022-11-04 16:07:03
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 0 0 0 10M 0 0 0 0 0
costOfRevenue 0 2M 2M 5M 2M 2M 0 0 0
grossProfit 0 -2M -2M 5M -2M -2M 0 0 0
grossProfitRatio 0 0 0 0.5 0 0 0 0 0
researchAndDevelopmentExpenses 42M 45M 44M 42M 47M 51M 46M 50M 43M
generalAndAdministrativeExpenses 27M 27M 22M 22M 19M 17M 16M 19M 15M
sellingAndMarketingExpenses 0 -786 000 -787 000 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 27M 27M 21M 22M 19M 17M 16M 19M 15M
otherExpenses 0 0 0 0 0 0 0 -500 000 0
operatingExpenses 69M 71M 65M 63M 65M 69M 62M 69M 58M
costAndExpenses 69M 74M 67M 63M 65M 69M 62M 69M 58M
interestIncome 3M 5M 6M 4M 4M 4M 4M 1M 1M
interestExpense 471 000 471 000 471 000 470 000 -469 000 468 000 468 000 -614 000 621 000
depreciationAndAmortization 2M 2M 2M 43 812 2M 2M 6M 5M 2M
ebitda -64M -67M -65M -57M -65M -64M -56M -64M -56M
ebitdaratio 0 0 0 -5.552 0 0 0 0 0
operatingIncome -69M -74M -67M -63M -65M -69M -62M -69M -58M
operatingIncomeRatio 0 0 0 -6.136 0 0 0 0 0
totalOtherIncomeExpensesNet 3M 4M 5M 4M 4M 3M 4M 2M 732 000
incomeBeforeTax -67M -70M -62M -60M -62M -66M -58M -67M -58M
incomeBeforeTaxRatio 0 0 0 -5.785 0 0 0 0 0
incomeTaxExpense 0 0 1 2M -2M 4M -3M -2M -732 000
netIncome -67M -70M -62M -60M -62M -66M -55M -64M -57M
netIncomeRatio 0 0 0 -5.785 0 0 0 0 0
eps -0.71 -0.74 -0.66 -0.64 -0.75 -0.82 -0.69 -0.94 -0.86
epsdiluted -0.71 -0.74 -0.66 -0.64 -0.75 -0.82 -0.69 -0.94 -0.86
weightedAverageShsOut 94M 94M 94M 93M 83M 80M 79M 68M 66M
weightedAverageShsOutDil 94M 94M 94M 93M 83M 80M 79M 68M 66M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-07 2024-08-06 2024-05-07 2024-02-27 2023-11-07 2023-08-09 2023-05-05 2023-02-28 2022-11-04
acceptedDate 2024-11-07 16:45:24 2024-08-06 16:15:31 2024-05-07 16:05:55 2024-02-27 16:05:52 2023-11-07 16:40:36 2023-08-09 17:21:03 2023-05-05 16:41:24 2023-02-28 17:31:33 2022-11-04 16:07:03
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 66M 39M 35M 56M 226M 45M 65M 141M 197M
shortTermInvestments 170M 240M 295M 317M 212M 262M 267M 216M 110M
cashAndShortTermInvestments 236M 279M 330M 373M 437M 307M 331M 356M 307M
netReceivables 0 8M 9M 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0
otherCurrentAssets 6M 6M 6M 5M 10M 5M 7M 8M 5M
totalCurrentAssets 242M 293M 345M 378M 447M 312M 338M 364M 311M
propertyPlantEquipmentNet 86M 88M 88M 88M 86M 83M 81M 78M 74M
goodwill 39M 39M 39M 39M 39M 39M 39M 39M 31M
intangibleAssets 25M 25M 25M 25M 25M 26M 26M 26M 0
goodwillAndIntangibleAssets 64M 64M 64M 64M 64M 65M 65M 65M 31M
longTermInvestments 0 1M 1M 34M 1M 1M 29M 43M 0
taxAssets 0 -1 0 533 000 -1M -1M 0 0 0
otherNonCurrentAssets 2M 481 000 533 000 1M 2M 2M 2M 2M 2M
totalNonCurrentAssets 152M 154M 154M 188M 152M 150M 177M 188M 106M
otherAssets 0 1 0 0 0 0 0 0 0
totalAssets 394M 446M 499M 566M 599M 462M 515M 552M 417M
accountPayables 0 0 3M 1772 1853 1115 0 37M 0
shortTermDebt 3M 6M 3M 3M 3M 3M 3M 3M 2M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 -3M -1772 -1853 -1115 0 -37M 0
otherCurrentLiabilities 37M 32M 30M 46M 31M 31M 29M 37M 28M
totalCurrentLiabilities 40M 38M 33M 49M 33M 34M 31M 39M 30M
longTermDebt 23M 23M 23M 22M 22M 22M 23M 20M 20M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 1M 1M 2M 3M 2M 2M 2M 3M 17M
totalNonCurrentLiabilities 24M 24M 25M 25M 24M 24M 25M 23M 20M
otherLiabilities 0 0 1 0 0 0 0 0 0
capitalLeaseObligations 26M 26M 23M 25M 25M 25M 25M 23M 22M
totalLiabilities 64M 62M 58M 74M 58M 59M 56M 62M 50M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 911 000 910 000 906 000 903 000 901 000 805 000 804 000 791 000 678 000
retainedEarnings -1 158M -1 091M -1 021M -959M -900M -838M -772M -714M -647M
accumulatedOtherComprehensiveIncomeLoss 213 000 -218 000 -135 000 319 000 -508 000 -722 000 -90 000 -357 000 -596 000
othertotalStockholdersEquity 1 486M 1 475M 1 462M 1 451M 1 440M 1 241M 1 230M 1 203M 1 014M
totalStockholdersEquity 330M 385M 442M 493M 541M 403M 459M 490M 367M
totalEquity 330M 385M 442M 493M 541M 403M 459M 490M 367M
totalLiabilitiesAndStockholdersEquity 394M 446M 499M 566M 599M 462M 515M 552M 417M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 394M 446M 499M 566M 599M 462M 515M 552M 417M
totalInvestments 170M 242M 296M 34M 212M 262M 29M 259M 110M
totalDebt 26M 26M 26M 25M 25M 25M 25M 23M 22M
netDebt -40M -13M -9M -31M -200M -20M -39M -118M -175M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-07 2024-08-06 2024-05-07 2024-02-27 2023-11-07 2023-08-09 2023-05-05 2023-02-28 2022-11-04
acceptedDate 2024-11-07 16:45:24 2024-08-06 16:15:31 2024-05-07 16:05:55 2024-02-27 16:05:52 2023-11-07 16:40:36 2023-08-09 17:21:03 2023-05-05 16:41:24 2023-02-28 17:31:33 2022-11-04 16:07:03
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -67M -70M -62M -60M -62M -66M -58M -67M -58M
depreciationAndAmortization 2M 2M 2M 2M 2M 2M 2M 3M 1M
deferredIncomeTax 0 0 0 -12M 12M 0 0 0 0
stockBasedCompensation 11M 11M 10M 10M 10M 10M 9M 10M 8M
changeInWorkingCapital 248 000 4M -5M 22M -6M 5M -7M 170 000 4M
accountsReceivables 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0
accountsPayables 0 0 -2M 18M 0 0 -8M 7M 0
otherWorkingCapital 248 000 4M -5M 4M -6M 5M 8M -7M 0
otherNonCashItems 755 000 14M 12M 9M -14M -2M -2M -3M 690 000
netCashProvidedByOperatingActivities -52M -54M -57M -29M -57M -51M -58M -56M -44M
investmentsInPropertyPlantAndEquipment -2M -2M -2M -5M -5M -4M -3M -3M -503 000
acquisitionsNet 0 0 0 81 234 -52 909 -35 325 7000 43M 0
purchasesOfInvestments -19M -39M -64M -209M -13M -73M -96M -199M -34M
salesMaturitiesOfInvestments 100M 96M 101M 72M 66M 108M 62M 51M 58M
otherInvestingActivites 0 0 37 069 -81 234 52 909 35 325 -7000 0 0
netCashUsedForInvestingActivites 79M 56M 35M -141M 48M 31M -37M -109M 23M
debtRepayment 0 29 000 -27 000 -109 000 -35 000 -37 000 0 0 0
commonStockIssued 176 000 2M 1M 391 000 189M 182 000 18M 108M 30M
commonStockRepurchased 0 0 0 0 0 0 0 -47 000 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 120 000 0 1184 109 000 35 000 37 000 7000 631 000 0
netCashUsedProvidedByFinancingActivities 120 000 2M 1M 391 000 189M 182 000 18M 108M 30M
effectOfForexChangesOnCash 0 0 0 167M -167M 0 0 0 0
netChangeInCash 27M 3M -21M -170M 181M -19M -76M -56M 9M
cashAtEndOfPeriod 67M 39M 35M 57M 227M 46M 66M 142M 198M
cashAtBeginningOfPeriod 40M 35M 56M 227M 46M 66M 142M 198M 189M
operatingCashFlow -52M -54M -57M -29M -57M -51M -58M -56M -44M
capitalExpenditure -2M -2M -2M -5M -5M -4M -3M -3M -503 000
freeCashFlow -54M -56M -59M -34M -62M -55M -61M -59M -44M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-09-17 11:00 ET
Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease
2024-09-10 11:00 ET
Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors
2024-08-27 11:00 ET
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
2024-08-05 20:01 ET
Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
2024-06-28 11:27 ET
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
2024-05-29 11:00 ET
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
2024-05-10 10:00 ET
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
2024-05-06 20:01 ET
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
2024-04-02 10:00 ET
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
2024-03-26 20:01 ET
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
2024-02-26 21:01 ET
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
2024-02-13 12:00 ET
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
2024-01-02 21:01 ET
Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-12 12:00 ET
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
2023-11-06 21:04 ET
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
2023-10-19 11:00 ET
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
2023-10-02 11:00 ET
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
2023-09-26 20:01 ET
Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference
2023-09-13 04:01 ET
Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2023-09-12 20:02 ET
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
2023-09-12 20:01 ET
Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease
2023-09-06 20:05 ET
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-08-10 11:00 ET
Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
2023-06-08 11:00 ET
Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
2023-05-31 11:00 ET
Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease
2023-05-23 11:00 ET
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD)
2023-05-19 10:00 ET
Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
2023-05-09 11:00 ET
Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
2023-05-04 20:01 ET
Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress
2023-05-03 20:01 ET
Rocket Pharmaceuticals to Participate in the Bank of America Securities 2023 Healthcare Conference
2023-04-11 20:01 ET
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-04-04 20:01 ET
Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage
2023-03-01 21:01 ET
Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference
2023-02-27 21:01 ET
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
2023-02-09 21:01 ET
Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
2023-02-07 12:00 ET
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease
2023-01-09 21:01 ET
Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease
2023-01-03 21:01 ET
Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
2022-12-22 11:00 ET
Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting
2022-12-12 15:00 ET
Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting
2022-12-01 21:01 ET
Rocket Pharmaceuticals Completes Acquisition of Renovacor
2022-11-21 13:00 ET
Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
2022-11-03 20:01 ET
Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
2022-11-03 13:00 ET
Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses
2022-10-12 10:00 ET
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
2022-10-10 12:00 ET
Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa
2022-10-04 03:21 ET
 Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2022-10-03 20:42 ET
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
2022-09-30 10:00 ET
 Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
2022-09-27 12:00 ET
Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference
2022-09-20 10:00 ET
Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy
2022-09-16 12:00 ET
Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
2022-09-06 12:00 ET
Rocket Pharmaceuticals to Present at Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-08 20:01 ET
Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
2022-07-27 11:00 ET
Rocket Pharmaceuticals Appoints Mayo Pujols as Chief Technical Officer and Strengthens Manufacturing Capabilities
2022-07-08 11:00 ET
Rocket Pharmaceuticals to Present at William Blair Biotech Focus Conference
2022-05-19 10:00 ET
Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
2022-05-16 10:00 ET
Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
2022-05-11 11:00 ET
Rocket Pharmaceuticals to Present at UBS Global Healthcare Conference
2022-05-05 20:01 ET
Rocket Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Progress
2022-04-27 11:00 ET
Rocket Pharmaceuticals to Present at the Bank of America Securities 2022 Global Healthcare Conference
2022-03-29 11:00 ET
Rocket Pharmaceuticals to Present at Upcoming Investor Conferences
2022-03-14 11:00 ET
Rocket Pharmaceuticals Appoints Fady Malik, M.D., Ph.D., to Board of Directors
2022-03-08 12:00 ET
Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance
2022-02-24 12:00 ET
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial and Operational Results
2022-02-10 12:00 ET
Rocket Pharmaceuticals Announces Participation in 11th Annual SVB Leerink Global Healthcare Conference
2022-01-11 12:00 ET
Rocket Pharmaceuticals Highlights Anticipated 2022 Milestones Across Lentiviral and AAV Gene Therapy Clinical Programs
2022-01-04 12:00 ET
Rocket Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-13 14:00 ET
Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting
2021-12-08 12:00 ET
Rocket Pharmaceuticals Appoints Martin L. Wilson as General Counsel and Chief Compliance Officer
2021-12-07 12:00 ET
Rocket Pharmaceuticals to Host In-Person Investor and Analyst Event and Webcast on Tuesday, Dec. 14 at 7:30 a.m. ET to Discuss Updated Clinical Data Presented at the 63rd American Society of Hematology (ASH) Annual Meeting
2021-11-22 12:00 ET
Rocket Pharmaceuticals Announces Participation in Evercore ISI 4th Annual HEALTHCONx Virtual Conference
2021-11-15 12:00 ET
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease
2021-11-11 12:00 ET
Rocket Pharmaceuticals to Host Webcast on Nov. 15 at 8:30 a.m. ET to Present Updated Danon Disease Clinical Data
2021-11-10 12:00 ET
Rocket Pharmaceuticals Announces Participation in Stifel 2021 Virtual Healthcare Conference
2021-11-08 10:00 ET
Rocket Pharmaceuticals Announces Danon Disease Presentation at the American Heart Association (AHA) Scientific Sessions 2021
2021-11-04 13:00 ET
Rocket Pharmaceuticals Announces Presentations Highlighting Three Lentiviral Gene Therapies at the 63rd American Society of Hematology (ASH) Annual Meeting
2021-11-03 11:00 ET
Rocket Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Progress
2021-10-20 07:00 ET
Rocket Pharmaceuticals Announces Positive Clinical Data from RP-L201 Trial for the Treatment of LAD-I at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
2021-10-19 10:00 ET
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
2021-10-07 11:00 ET
Rocket Pharmaceuticals to Present at the 2021 Cell & Gene Meeting on the Mesa
2021-09-30 11:00 ET
Rocket Pharmaceuticals to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
2021-09-14 11:00 ET
Rocket Pharmaceuticals Presents Clinical Data from RP-A501 Trial in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021
2021-09-10 11:00 ET
Rocket Pharmaceuticals Announces Upcoming Danon Disease Presentation at the Heart Failure Society of America Annual Scientific Meeting 2021
2021-09-07 11:00 ET
Rocket Pharmaceuticals Appoints Isabel Carmona, J.D., as Chief Human Resources Officer
2021-08-30 11:00 ET
Rocket Pharmaceuticals Announces $26.4 Million Private Placement
2021-08-16 11:00 ET
Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Danon Disease Trial of RP-A501
2021-08-09 20:01 ET
Rocket Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Progress
2021-08-03 20:01 ET
Rocket Pharmaceuticals to Host Conference Call on Aug. 9 at 4:30 p.m. ET to Discuss Second Quarter Results and Recent Business Highlights
2021-05-13 11:00 ET
Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24th Annual Meeting of the American Society of Gene and Cell Therapy
2021-05-10 20:00 ET
Rocket Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Progress
2021-04-27 20:30 ET
Rocket Pharmaceuticals Announces Upcoming Clinical Data Presentations at the 24th Annual Meeting of the American Society of Gene and Cell Therapy
2021-04-14 11:00 ET
Rocket Pharmaceuticals Reports Positive Long-Term Clinical Data from RP-L201 Trial for the Treatment of Leukocyte Adhesion Deficiency-I at the Clinical Immunology Society 2021 Annual Meeting
2021-03-29 11:00 ET
Rocket Pharmaceuticals Receives EMA Priority Medicines (PRIME) Designation for RP-L201 Gene Therapy for Treatment of Leukocyte Adhesion Deficiency-I
2021-03-22 11:00 ET
Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency
2021-03-09 12:00 ET
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I
2021-02-25 12:00 ET
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
2021-02-18 12:00 ET
Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
2021-01-11 12:00 ET
Rocket Pharmaceuticals Announces Buildout of R&D and Manufacturing Facility to Support Development of Innovative Gene Therapy Pipeline
2021-01-06 12:00 ET
Rocket Pharmaceuticals Announces Participation at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-14 21:01 ET
Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
2020-12-10 04:32 ET
Rocket Pharmaceuticals Prices Upsized Public Offering of Common Stock
2020-12-09 12:51 ET
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
2020-12-08 21:00 ET
Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for the Treatment of Danon Disease
2020-12-07 19:30 ET
Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American Society of Hematology Annual Meeting
2020-12-06 15:00 ET
Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual Meeting
2020-12-02 12:00 ET
Rocket Pharmaceuticals to Hold Webcast for Investors Highlighting Data Presented at the 62nd American Society of Hematology Annual Meeting
2020-11-24 12:00 ET
Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
2020-11-13 12:00 ET
Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis
2020-11-04 15:37 ET
Rocket Pharmaceuticals to Present Data from its Fanconi Anemia, Leukocyte Adhesion Deficiency-I and Pyruvate Kinase Deficiency Programs at the 62nd American Society of Hematology Annual Meeting
2020-11-04 12:00 ET
Rocket Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Progress
2020-10-16 11:00 ET
Rocket Pharmaceuticals Presents Positive LAD-l Clinical Update and Comprehensive IMO Preclinical Review at the European Society for Immunodeficiencies 2020 Meeting
2020-10-01 11:00 ET
Rocket Pharmaceuticals Announces Two Presentations at the European Society for Immunodeficiencies 2020 Meeting
2020-09-24 11:00 ET
Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
2020-09-04 11:00 ET
Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
2020-09-02 11:00 ET
Rocket Pharmaceuticals Announces First Patient Treated in Higher Dose Cohort in Phase 1 Clinical Trial of RP-A501 for Danon Disease
2020-08-27 11:00 ET
Rocket Pharmaceuticals Receives FDA Fast Track Designation for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis
2020-08-26 11:00 ET
Rocket Pharmaceuticals Expands Clinical Sites for its FA, Danon, LAD-I and IMO Trials, Adding to its Global Centers of Excellence
2020-08-05 11:00 ET
Rocket Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Progress
2020-07-13 11:00 ET
Rocket Pharmaceuticals Announces First Patient Treated in Phase 1 Trial of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency
2020-06-29 11:00 ET
Rocket Pharmaceuticals Announces FDA Clearance of IND for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis
2020-06-08 11:00 ET
Rocket Pharmaceuticals Announces Private Exchange Transaction Regarding Its Outstanding Convertible Senior Notes due 2021
2020-05-26 11:00 ET
Rocket Pharmaceuticals Announces Participation at the Jefferies Virtual Healthcare Conference
2020-05-12 11:00 ET
Rocket Pharmaceuticals Presents Positive Updates on FA and LAD-I Gene Therapy Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy
2020-05-06 11:00 ET
Rocket Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Progress
2020-05-05 11:00 ET
Rocket Pharmaceuticals Announces Participation at the BofA Securities 2020 Health Care Conference
2020-04-22 11:00 ET
Rocket Pharmaceuticals Appoints Elisabeth Bjӧrk, M.D., Ph.D. to Board of Directors
2020-04-02 13:00 ET
Rocket Pharmaceuticals Provides Business Update in Light of COVID-19 Pandemic
2020-04-02 11:30 ET
Rocket Pharmaceuticals Announces Participation at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day
2020-03-19 11:00 ET
Rocket Pharmaceuticals Announces Science Translational Medicine Publication of its Program in Danon Disease
2020-03-05 12:00 ET
Rocket Pharmaceuticals Reports Full Year 2019 Financial Results and Operational Highlights
2020-02-24 12:00 ET
Rocket Pharmaceuticals Announces Publication of Manuscript Evaluating Mosaicism in Fanconi Anemia
2020-02-18 12:00 ET
Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
2020-02-11 14:15 ET
Rocket Pharmaceuticals Announces Private Exchange Transactions Regarding Outstanding Convertible Senior Notes due 2021
2020-02-06 12:00 ET
Rocket Pharmaceuticals Supports Rare Disease Day® and Joins Global Movement to Raise Awareness
2020-01-06 12:00 ET
Rocket Pharmaceuticals Announces Participation at the 38th Annual J.P. Morgan Healthcare Conference
2019-12-16 12:00 ET
Rocket Pharmaceuticals Receives the European Medicines Agency PRIME Eligibility for RP-L102 Gene Therapy for Fanconi Anemia
2019-12-13 21:01 ET
Rocket Pharmaceuticals Announces Closing of Public Offering
2019-12-11 03:45 ET
Rocket Pharmaceuticals Prices Public Offering of Common Stock
2019-12-10 21:01 ET
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
2019-12-09 12:00 ET
Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I
2019-12-08 23:00 ET
Rocket Pharmaceuticals Presents Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 “Process B” for Fanconi Anemia at 61st American Society of Hematology Annual Meeting
2019-12-06 12:00 ET
Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 “Process B” for Fanconi Anemia
2019-12-05 12:00 ET
Rocket Pharmaceuticals to Host Breakout Session at 61st American Society of Hematology Annual Meeting
2019-11-27 12:00 ET
Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
2019-11-07 12:00 ET
Rocket Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights
2019-11-06 14:00 ET
Rocket Pharmaceuticals to Present Preliminary Phase 1 Data of RP-L102 “Process B” for Fanconi Anemia at the 61st American Society of Hematology Annual Meeting
2019-11-05 12:00 ET
Rocket Pharmaceuticals Announces Participation at the Barclays Gene Editing & Gene Therapy Summit
2019-10-24 11:00 ET
Rocket Pharmaceuticals Presents First Evidence of Long-Term Improvement and Stabilization in Blood Counts and Durable Mosaicism in RP-L102 “Process A” for Fanconi Anemia
2019-10-22 11:00 ET
Rocket Pharmaceuticals Announces Clearance of IND for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency
2019-10-15 11:00 ET
Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress
2019-10-01 11:00 ET
Rocket Pharmaceuticals Announces Participation at the Chardan 3rd Annual Genetic Medicines Conference
2019-09-23 11:00 ET
 Rocket Pharmaceuticals Announces IMPD Clearance of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency
2019-09-10 11:00 ET
Rocket Pharmaceuticals Announces Publication of Data from Phase 1/2 Trial of First-Generation RP-L102 for Fanconi Anemia in Nature Medicine

SEC forms

Show financial reports only

SEC form 8
2025-07-24 11:10 ET
Rocket Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-24 11:10 ET
Rocket Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-17 11:46 ET
Rocket Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-17 11:46 ET
Rocket Pharmaceuticals published news for 2025 q2
SEC form 8
2025-05-27 11:40 ET
Rocket Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-27 11:40 ET
Rocket Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-15 20:57 ET
Rocket Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-15 20:57 ET
Rocket Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-15 20:57 ET
Rocket Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-08 20:02 ET
Rocket Pharmaceuticals reported for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Rocket Pharmaceuticals reported for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Rocket Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Rocket Pharmaceuticals published news for 2025 q1
SEC form 10
2025-02-27 21:01 ET
Rocket Pharmaceuticals reported for 2024 q4
SEC form 10
2025-02-27 00:00 ET
Rocket Pharmaceuticals reported for 2024 q4
SEC form 8
2025-02-27 00:00 ET
Rocket Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-27 00:00 ET
Rocket Pharmaceuticals published news for 2024 q4
SEC form 10
2024-11-07 16:45 ET
Rocket Pharmaceuticals reported for 2024 q3
SEC form 8
2024-11-07 16:20 ET
Rocket Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-07 16:20 ET
Rocket Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-06 16:15 ET
Rocket Pharmaceuticals reported for 2024 q2
SEC form 10
2024-08-06 00:00 ET
Rocket Pharmaceuticals reported for 2024 q2
SEC form 8
2024-08-05 00:00 ET
Rocket Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-05 00:00 ET
Rocket Pharmaceuticals published news for 2024 q2
SEC form 10
2024-05-07 16:05 ET
Rocket Pharmaceuticals reported for 2024 q1
SEC form 10
2024-05-07 00:00 ET
Rocket Pharmaceuticals reported for 2024 q1
SEC form 8
2024-05-06 17:26 ET
Rocket Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-06 17:26 ET
Rocket Pharmaceuticals published news for 2024 q1
SEC form 10
2024-02-27 16:05 ET
Rocket Pharmaceuticals reported for 2023 q4
SEC form 10
2024-02-27 00:00 ET
Rocket Pharmaceuticals reported for 2023 q4
SEC form 8
2024-02-26 00:00 ET
Rocket Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-26 00:00 ET
Rocket Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-07 16:40 ET
Rocket Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Rocket Pharmaceuticals reported for 2023 q3
SEC form 10
2023-08-09 17:21 ET
Rocket Pharmaceuticals reported for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Rocket Pharmaceuticals reported for 2023 q2
SEC form 6
2023-06-23 16:27 ET
Rocket Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-05 00:00 ET
Rocket Pharmaceuticals reported for 2023 q1
SEC form 6
2023-04-04 17:14 ET
Rocket Pharmaceuticals published news for 2023 q1
SEC form 6
2023-03-10 11:59 ET
Rocket Pharmaceuticals published news for 2022 q4
SEC form 10
2023-02-28 17:31 ET
Rocket Pharmaceuticals reported for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Rocket Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-27 17:22 ET
Rocket Pharmaceuticals published news for 2022 q4
SEC form 8
2023-02-27 00:00 ET
Rocket Pharmaceuticals published news for 2022 q4
SEC form 6
2023-02-07 16:50 ET
Rocket Pharmaceuticals published news for 2022 q4
SEC form 6
2023-01-09 16:29 ET
Rocket Pharmaceuticals published news for 2022 q4
SEC form 6
2022-12-22 16:06 ET
Rocket Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-01 16:31 ET
Rocket Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-04 16:07 ET
Rocket Pharmaceuticals reported for 2022 q3
SEC form 10
2022-11-04 00:00 ET
Rocket Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-03 17:10 ET
Rocket Pharmaceuticals published news for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Rocket Pharmaceuticals published news for 2022 q3
SEC form 6
2022-10-04 17:28 ET
Rocket Pharmaceuticals published news for 2022 q3
SEC form 6
2022-10-03 16:38 ET
Rocket Pharmaceuticals published news for 2022 q3
SEC form 6
2022-09-20 16:52 ET
Rocket Pharmaceuticals published news for 2022 q2
SEC form 6
2022-09-09 08:21 ET
Rocket Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-09 16:28 ET
Rocket Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Rocket Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-08 17:17 ET
Rocket Pharmaceuticals published news for 2022 q2
SEC form 8
2022-08-08 00:00 ET
Rocket Pharmaceuticals published news for 2022 q2
SEC form 6
2022-06-15 21:07 ET
Rocket Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-15 21:07 ET
Rocket Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-15 21:07 ET
Rocket Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-15 21:07 ET
Rocket Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-15 21:07 ET
Rocket Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-15 21:07 ET
Rocket Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-15 16:41 ET
Rocket Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-06 16:05 ET
Rocket Pharmaceuticals reported for 2022 q1
SEC form 10
2022-05-06 00:00 ET
Rocket Pharmaceuticals reported for 2022 q1
SEC form 6
2022-04-29 16:07 ET
Rocket Pharmaceuticals published news for 2022 q1
SEC form 6
2022-03-11 19:09 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-11 16:05 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-09 16:53 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-28 18:40 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-28 16:10 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 17:19 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-16 21:32 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-16 21:03 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-16 21:02 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-16 21:02 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-08 16:43 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2021-12-08 18:53 ET
Rocket Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-05 16:13 ET
Rocket Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-05 16:02 ET
Rocket Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-05 00:00 ET
Rocket Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Rocket Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-03 21:49 ET
Rocket Pharmaceuticals published news for 2021 q3
SEC form 6
2021-08-30 07:10 ET
Rocket Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-09 16:20 ET
Rocket Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-09 16:11 ET
Rocket Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-09 00:00 ET
Rocket Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-09 00:00 ET
Rocket Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-21 16:28 ET
Rocket Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-10 16:46 ET
Rocket Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-10 16:42 ET
Rocket Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
Rocket Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-10 00:00 ET
Rocket Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-30 16:22 ET
Rocket Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-27 16:18 ET
Rocket Pharmaceuticals published news for 2021 q1
SEC form 10
2021-03-01 17:03 ET
Rocket Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-07 06:02 ET
Rocket Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-06 20:19 ET
Rocket Pharmaceuticals published news for 2020 q4
SEC form 6
2020-12-11 08:22 ET
Rocket Pharmaceuticals published news for 2020 q3
SEC form 6
2020-12-11 08:16 ET
Rocket Pharmaceuticals published news for 2020 q3
SEC form 6
2020-12-09 08:24 ET
Rocket Pharmaceuticals published news for 2020 q3
SEC form 10
2020-11-06 16:08 ET
Rocket Pharmaceuticals published news for 2020 q3